Isebia et al., 2022 - Google Patents
Characterizing circulating tumor cells and tumor-derived extracellular vesicles in metastatic castration-naive and castration-resistant prostate cancer patientsIsebia et al., 2022
View HTML- Document ID
- 10334288473939441816
- Author
- Isebia K
- Dathathri E
- Verschoor N
- Nanou A
- De Jong A
- Coumans F
- Terstappen L
- Kraan J
- Martens J
- Bansal R
- Lolkema M
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary The composition of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in the blood of 104 patients with metastatic castration-naive prostate cancer and 66 patients with metastatic castration-resistant prostate cancer was …
- 208000005443 Circulating Neoplastic Cells 0 title abstract description 33
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/10—Office automation, e.g. computer aided management of electronic mail or groupware; Time management, e.g. calendars, reminders, meetings or time accounting
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/30—Information retrieval; Database structures therefor; File system structures therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rathore et al. | Glioma grading via analysis of digital pathology images using machine learning | |
Costa et al. | Analysis of a real-world cohort of metastatic breast cancer patients shows circulating tumor cell clusters (CTC-clusters) as predictors of patient outcomes | |
Muinelo-Romay et al. | Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment | |
Lowes et al. | Circulating tumor cells (CTC) and cell-free DNA (cfDNA) workshop 2016: scientific opportunities and logistics for cancer clinical trial incorporation | |
Stevens et al. | StarDist image segmentation improves circulating tumor cell detection | |
Castello et al. | Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors | |
Acs et al. | Variability in breast cancer biomarker assessment and the effect on oncological treatment decisions: a nationwide 5-year population-based study | |
Rapoport et al. | Tumor-infiltrating lymphocytes (Tils) in early breast cancer patients: High Cd3+, Cd8+, and immunoscore are associated with a pathological complete response | |
de Glas et al. | Toxicity, response and survival in older patients with metastatic melanoma treated with checkpoint inhibitors | |
Stawski et al. | Current trends in cell-free DNA applications. scoping review of clinical trials | |
Okegawa et al. | Epidermal growth factor receptor status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with docetaxel chemotherapy | |
Zhang et al. | Radiomic model predicts lymph node response to induction chemotherapy in locally advanced head and neck cancer | |
Kasprzak et al. | The histochemical alterations of mucin in colorectal carcinoma quantified by two efficient algorithms of digital image analysis | |
Tang et al. | Clinical applications of cancer-associated cells present in the blood of cancer patients | |
Katsarou et al. | Detyrosinated α-tubulin, vimentin and PD-L1 in circulating tumor cells (CTCs) isolated from non-small cell lung cancer (NSCLC) patients | |
Boquet et al. | Comparison of immune response assessment in colon cancer by immunoscore (automated digital pathology) and pathologist visual scoring | |
Hack et al. | When SUV matters: FDG PET/CT at baseline correlates with survival in soft tissue and ewing sarcoma | |
Nanou et al. | Leukocyte-derived extracellular vesicles in blood with and without EpCAM enrichment | |
Emamifar et al. | Prevalence of newly diagnosed malignancies in patients with polymyalgia rheumatica and giant cell arteritis, comparison of 18F-FDG PET/CT scan with chest X-ray and abdominal ultrasound: data from a 40 week prospective, exploratory, single centre study | |
Narbe et al. | The distribution of circulating tumor cells is different in metastatic lobular compared to ductal carcinoma of the breast—long-term prognostic significance | |
Isebia et al. | Characterizing circulating tumor cells and tumor-derived extracellular vesicles in metastatic castration-naive and castration-resistant prostate cancer patients | |
Banys-Paluchowski et al. | Circulating tumor cells in metastatic breast cancer: clinical applications and future possibilities | |
Papadaki et al. | Assessment of the efficacy and clinical utility of different circulating tumor cell (CTC) detection assays in patients with chemotherapy-naive advanced or metastatic non-small cell lung cancer (NSCLC) | |
Morrison et al. | Non-invasive profiling of advanced prostate cancer via multi-parametric liquid biopsy and radiomic analysis | |
D’amico et al. | Single-cells isolation and molecular analysis: focus on HER2-low CTCs in metastatic breast cancer |